MedTrace Logo

Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders

NCT00636909 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-04-06

No results posted yet for this study

Summary

The purpose of this study is to provide allogeneic stem cell transplantation to patients who have not traditionally undergone this procedure because of it high incidence of treatment related side effects. We hope to decrease these side effects by decreasing the chemotherapy dose prior to transplant (non-myeloablative, smaller dose of chemotherapy given so bone marrow is not completely eliminated) and by using donated stem cells to treat cancer of the blood.

Conditions

  • AML
  • ALL
  • CML Chronic Phase, Accelerated Phase, or Blast Crisis
  • CLL
  • MDS
  • RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA
  • APLASTIC ANEMIA
  • MULTIPLE MYELOMA
  • MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)

Interventions

DRUG

Cyclophosphamide

preparative cytoreduction

DRUG

fludarabine

preparative cytoreduction

DRUG

cyclosporine

immunosuppressive therapy

DRUG

methotrexate

immunosuppressive therapy

BIOLOGICAL

G-CSF

foster engraftment

Sponsors & Collaborators

Principal Investigators

  • David F McDermott, MD · Beth Israel Deaconess Medical Center

  • David E Avigan, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-07-31
Primary Completion
2006-03-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00636909 on ClinicalTrials.gov